Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia |
| |
Authors: | Zinzani P L Bendandi M Magagnoli M Albertini P Rondelli D Stefoni V Tani M Tura S |
| |
Affiliation: | Istituto di Ematologia e Oncologia Medica "Seràgnoli", Policlinico S. Orsola, Via Massarenti 9, 40121 Bologna, Italy. plzinzo@med.unibo.it |
| |
Abstract: | BACKGROUND AND OBJECTIVES: A study update to assess long-term survival following fludarabine salvage treatment in previously treated patients with chronic lymphocytic lymphoma (CLL). DESIGN AND METHODS: From September 1992 to December 1995, 74 patients with advanced, relapsing B-cell CLL were enrolled in the study. Fludarabine was given for 5 consecutive days at the dose of 25 mg/m2/day in a 30 min infusion. Treatment was repeated every 28 days for a maximum of 6 courses.E RESULTS. Nineteen (26%) patients achieved a complete response (CR) and 20 (27%) patients had a partial response (PR), giving an overall response rate of 53%. The median overall survival was 68 months, and there was a strong negative correlation with the number of previous treatments. The median time to progression was 18 months for patients who achieved a CR and 12 months for those with a PR. INTERPRETATION AND CONCLUSIONS: The results obtained with fludarabine alone in this subset of CLL patients indicate the existence of a conspicuous disease-free survival period. This time window could be used to consolidate the initial response with either biological approaches or high-dose therapeutic strategies such as autologous bone marrow transplantation, with the aim of eventual eradication of the disease. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|